NI advisor has new way to treat ovarian cancer

A chance meeting between a member of NI's editorial advisory board and the program director of the Seton Hall Internal Medicine Residency  Program has led to promising data on a new way to treat ovarian cancer,  the Westfield Leader reports.

Our own Stephen DeFelice had conducted animal studies in the use of the  agent carnitine to reverse myocardial ischemia during the Vietnam War.  Dr DeFelice later postulated that the compound could be combined with  Adriamycin (doxorubicin) to increase the latter's efficacy while  decreasing its toxicity.

He arranged a clinical study at Vanderbilt University, in which, he told  the Westfield Leader, the results were "unexpectedly dramatic."  Nonetheless, he was unable to find a company to fund further research,  until that is, he ran into Ernest Federici of Seton Hall.